168 related articles for article (PubMed ID: 8465780)
1. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial).
Goldbourt U; Behar S; Reicher-Reiss H; Agmon J; Kaplinsky E; Graff E; Kishon Y; Caspi A; Weisbort J; Mandelzweig L
Am J Cardiol; 1993 Apr; 71(11):909-15. PubMed ID: 8465780
[TBL] [Abstract][Full Text] [Related]
2. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.
Ericsson CG; Hamsten A; Nilsson J; Grip L; Svane B; de Faire U
Lancet; 1996 Mar; 347(9005):849-53. PubMed ID: 8622389
[TBL] [Abstract][Full Text] [Related]
3. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.
Bezafibrate Infarction Prevention (BIP) study
Circulation; 2000 Jul; 102(1):21-7. PubMed ID: 10880410
[TBL] [Abstract][Full Text] [Related]
4. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
[TBL] [Abstract][Full Text] [Related]
5. Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).
Brodov Y; Behar S; Boyko V; Chouraqui P
Am J Cardiol; 2010 Dec; 106(12):1717-20. PubMed ID: 21126615
[TBL] [Abstract][Full Text] [Related]
6. Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress.
Ericsson CG
Eur Heart J; 1998 Jul; 19 Suppl H():H37-41. PubMed ID: 9717064
[TBL] [Abstract][Full Text] [Related]
7. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial).
Goldenberg I; Goldbourt U; Boyko V; Behar S; Reicher-Reiss H;
Am J Cardiol; 2006 Feb; 97(4):466-71. PubMed ID: 16461038
[TBL] [Abstract][Full Text] [Related]
8. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol.
Rubins HB; Robins SJ; Iwane MK; Boden WE; Elam MB; Fye CL; Gordon DJ; Schaefer EJ; Schectman G; Wittes JT
Am J Cardiol; 1993 Jan; 71(1):45-52. PubMed ID: 8420235
[TBL] [Abstract][Full Text] [Related]
9. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study.
Goldbourt U; Brunner D; Behar S; Reicher-Reiss H
Eur Heart J; 1998 Jul; 19 Suppl H():H42-7. PubMed ID: 9717065
[TBL] [Abstract][Full Text] [Related]
10. Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
de Faire U; Ericsson CG; Hamsten A; Nilsson J
Drugs Exp Clin Res; 1995; 21(3):105-24. PubMed ID: 7555614
[TBL] [Abstract][Full Text] [Related]
11. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study.
Arcavi L; Behar S; Caspi A; Reshef N; Boyko V; Knobler H
Am Heart J; 2004 Feb; 147(2):239-45. PubMed ID: 14760320
[TBL] [Abstract][Full Text] [Related]
12. Bezafibrate therapy in patients with isolated low high-density lipoprotein cholesterol levels may have a beneficial effect in prevention of atherosclerosis.
Weintraub MS; Grosskopf I; Charach G; Mor R; Rubinstein A; Wollman Y; Judevices R; Iaina A
Metabolism; 1995 Nov; 44(11):1401-9. PubMed ID: 7476325
[TBL] [Abstract][Full Text] [Related]
13. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
Ruotolo G; Ericsson CG; Tettamanti C; Karpe F; Grip L; Svane B; Nilsson J; de Faire U; Hamsten A
J Am Coll Cardiol; 1998 Nov; 32(6):1648-56. PubMed ID: 9822092
[TBL] [Abstract][Full Text] [Related]
14. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial.
Goldenberg I; Boyko V; Tennenbaum A; Tanne D; Behar S; Guetta V
Arch Intern Med; 2009 Mar; 169(5):508-14. PubMed ID: 19273782
[TBL] [Abstract][Full Text] [Related]
15. Differentiating the effects of raising low levels of high-density lipoprotein cholesterol versus lowering normal triglycerides: further insights from the Veterans Affairs High-Density Lipoprotein Intervention Trial.
Miller M
Am J Cardiol; 2000 Dec; 86(12A):23L-27L. PubMed ID: 11374852
[TBL] [Abstract][Full Text] [Related]
16. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
Goa KL; Barradell LB; Plosker GL
Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
[TBL] [Abstract][Full Text] [Related]
18. Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study.
Barasch E; Benderly M; Graff E; Behar S; Reicher-Reiss H; Caspi A; Pelled B; Reisin L; Roguin N; Goldbourt U
J Clin Epidemiol; 1995 Jun; 48(6):757-65. PubMed ID: 7769406
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study.
Elkeles RS; Diamond JR; Poulter C; Dhanjil S; Nicolaides AN; Mahmood S; Richmond W; Mather H; Sharp P; Feher MD
Diabetes Care; 1998 Apr; 21(4):641-8. PubMed ID: 9571357
[TBL] [Abstract][Full Text] [Related]
20. Low- and high-density lipoprotein cholesterol and ischemic cerebrovascular disease: the bezafibrate infarction prevention registry.
Koren-Morag N; Tanne D; Graff E; Goldbourt U
Arch Intern Med; 2002 May; 162(9):993-9. PubMed ID: 11996608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
